Wilder,
Here are the hits on EGFR in the title at ASCO presentations (5 each by OSIP and IMCL). The abstracts themselves seem not to be available on line - attendees have hard copy, though. (But note that presenters sometimes update the abstracts they had submitted months ago, so even the published abstracts may not contain all the news).
895 - Efficacy and Safety of the Anti-Epidermal Growth Factor Antibody (EGFR) IMC-C225, in Combination with Cisplatin in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) Refractory to Cisplatin Containing Chemotherapy.
Authors: Waun Ki Hong, Mathew Arquette, Lisle Nabell, Michael N. Needle, Harlan W. Waksal, Roy S. Herbst, MD Anderson Cancer Center, Houston, TX; Washington University, St. Louis, MO; University of Alabama, Birmingham, AL; ImClone Systems, Incorporated, Somerville
Faculty: Waun Ki Hong
Head and Neck Cancer
Oral Presentation - Palace Hotel, Grand Ballroom
Tuesday
7:45 AM -
11:45 AM 914 - Concomitant Radio-Chemotherapy (CRC) in Unresectable Squamous Cell Carcinoma of the Pharynx: Prognostic Impact of the Tumoral Epidermal Growth Factor Receptor (EGFR) Levels.
Authors: Nicolas Magné, Xavier Pivot, René-Jean Bensadoun, Emmanuel Guardiola, Gilles Poissonnet, Olivier Dassonville, François Demard, Antoine Thyss, Gérard Milano, Maurice Schneider, Centre Antoine Lacassagne, Nice, France.
Faculty: Nicolas Magné
Head and Neck Cancer
Poster Discussion Session - Marriott, Golden Gate Hall, Salon B
Tuesday
7:45 AM -
11:45 AM 1026 - C225 Anti-EGFR Antibody Potentiates Radiation (RT) And Chemotherapy (CT) Cytotoxicity In Human Non-Small Cell Lung Cancer (NSCLC) Cells In Vitro And In Vivo.
Authors: D Raben, B Helfrich, D Chan, M Phistry, A Kee, T Zhao, W Zundel, P Bunn, University of Colorado Comprehensive Cancer Center, Denver, CO.
Faculty: David Raben
ImmunoBiology
Poster Discussion Session - Marriott, Golden Gate Hall, Salon C1
Saturday
7:45 AM -
11:45 AM 544 - Feasibility and Pharmacokinetic (PK) Trial of ZD1839 (Iressa™), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Combination with 5-Fluorouracil (5-FU) and Leucovorin (LV) in Patients with Advanced Colorectal Cancer.
Authors: Lisa A. Hammond, J Figueroa, L Schwartzberg, L Ochoa, M Hidalgo, N Olivo, G Schwartz, L Smith, J Ochs, E K Rowinsky, Institute for Drug Development, San Antonio, TX; Joe Arrington Cancer Center, Lubbock, TX; Response Oncology, Memphis, TN; University of T
Faculty: Lisa A. Hammond
Gastrointestinal Cancer
Poster Session General - Marriott, Golden Gate Hall, Salon A
Saturday
7:45 AM -
11:45 AM 593 - Association Between mRNA Expression Level of Epidermal Growth Factor Receptor (EGFR), Immunohistochemistry (IHC) and Response to the EGFR-Inhibitor C225 in Advanced Colorectal Carcinoma.
Authors: Jan Stoehlmacher, Jan Brabender, Yoshinori Shirota, David J Park, Kathleen D Danenberg, Peter V Danenberg, Heinz-Josef Lenz, University of Southern California/Norris Cancer Center #5334, Los Angeles, CA; University of Southern California/Norris Cancer Cen
Faculty: Jan Stoehlmacher
Gastrointestinal Cancer
Poster Session General - Marriott, Golden Gate Hall, Salon A
Monday
8:00 AM -
12:00 PM 790 - Expression of HER2/neu (HER2) and EGFR in Osteosarcoma (OS).
Authors: James Christopher Wittig, Lorna Cruz, Felasfa Wodajo, Kristen Leigh Kellar-Graney, Nita Seibel, Martin Miles Malawer, Dhruv Kumar, Dennis Priebat, Washington Cancer Institute, Washington, DC; Children's National Medical Center, Washington, DC.
Faculty: James Christopher Wittig
Genitourinary Malignancies
Poster Session General - Moscone South, Exhibit Level, Hall B
Tuesday
8:00 AM -
11:30 AM 1301 - A Pilot Trial Demonstrates the Safety of ZD1839 (‘Iressa’), an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Combination with Carboplatin (C) and Paclitaxel (P) in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC).
Authors: V A Miller, D Johnson, R T Heelan, B A Pizzo, W J Perez, A Bass, M G Kris, J Ochs, S Averbuch, Memorial Sloan-Kettering Cancer Center, New York, NY; Vanderbilt University, Nashville, TN; AstraZeneca, Wilmington, DE.
Faculty: V. A. Miller
Small Cell and Non-Small Cell Lung Cancer
Poster Session General - Moscone South, Exhibit Level, Hall B
Monday
8:30 AM -
12:30 PM 831 - Phase 2 Evaluation of OSI-774, a Potent Oral Antagonist of the EGFR-TK in Patients with Advanced Ovarian Carcinoma.
Authors: Neil Finkler, Alan Gordon, Mark Crozier, Robert Edwards, Jose Figueroa, Agustin Garcia, John Hainsworth, David Irwin, Sandra Silberman, Lee Allen, Karen Ferrante, Douglas Fisher, Paul Nadler, Walt Disney Memorial Cancer Institute, Orlando, FL; US Oncology
Faculty: Neil Finkler
Gynecologic Cancers
Poster Discussion Session - Marriott, Golden Gate Hall, Salon C1
Monday
11:30 AM -
11:45 AM 281 - Inhibition of the Epidermal Growth Factor Receptor (EGFR) by OSI-774, a Specifc EGFR Inhibitor in Malignant and Normal Tissues of Cancer Patients.
Authors: Manuel Hidalgo, Shazly Malik, Erik Rowinsky, Alexander Miller, Dianne Duffey, Linda de'Grafenried, Lillian Siu, Cecelia Simmons, Jeffrey Kreisberg, Michael Brattain, University of Texas Health Science Center at San Antonio; Institute for Drug Development,
Faculty: Manuel Hidalgo
New Agents and Targets
Oral Presentation - Moscone South, Esplanade Ballroom
Monday
11:45 AM -
12:00 PM 282 - The EGFR-Selective Tyrosine Kinase Inhibitor ZD1839 (‘Iressa’) is an Effective Inhibitor of Tamoxifen-Resistant Breast Cancer Growth.
Authors: J M Gee, I R Hutcheson, J M Knowlden, D Barrow, M E Harper, A E Wakeling, R I Nicholson, Tenovus Centre for Cancer Research, Cardiff, UK; AstraZeneca, Alderley Park, Cheshire, UK.
Faculty: J. M. Gee
New Agents and Targets
Oral Presentation - Moscone South, Esplanade Ballroom
Saturday
1:00 PM -
1:10 PM 5 - Dose-Schedule-Finding, Pharmacokinetic (PK), Biologic, and Functional Imaging Studies of OSI-774, a Selective Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase (TK) Inhibitor.
Authors: Eric Keith Rowinsky, Lisa Hammond, Lillian Siu, Paul Jerabek, Jinee Rizzo, Louis Denis, John Nemunatis, Amita Patnaik, S Gail Eckhardt, Anthony Tolcher, Chris Takimoto, Karen Ferrante, Lee Lee Allen, Sandra Silberman, Manuel Hidalgo, Cancer Therapy and Re
Faculty: Eric Keith Rowinsky
Targeting the EGF Receptor: A Clinical Reality
Integrated Symposium - Moscone South, Esplanade Ballroom
Saturday
1:15 PM -
1:25 PM 6 - Phase 2 Evaluation of OSI-774, a Potent Oral Antagonist of the EGFR-TK in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck.
Authors: Neil N. Senzer, D Soulieres, L Siu, S Agarwala, E Vokes, M Hidalgo, S Silberman, L Allen, K Ferrante, D Fisher, C Marsolais, P Nadler, Texas Oncology, PA, Dallas, TX; Hopital Notre Dame, Montreal, Canada; Princess Margaret Hospital, Toronto, Canada; U Pit
Faculty: Neil N. Senzer
Targeting the EGF Receptor: A Clinical Reality
Integrated Symposium - Moscone South, Esplanade Ballroom
Saturday
1:30 PM -
1:40 PM 7 - Cetuximab (IMC-C225) Plus Irinotecan (CPT-11) is Active in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses Epidermal Growth Factor Receptor (EGFR).
Authors: Leonard Saltz, Mark Rubin, Howard Hochster, N Simon Tchekmeydian, Harlan Waksal, Michael Needle, Albert LoBuglio, Memorial Sloan Kettering Cancer Center, New York, NY; Florida Cancer Specialists, Fort Meyers, FL; New York University Medical Center, New Yo
Faculty: Leonard Saltz
Targeting the EGF Receptor: A Clinical Reality
Integrated Symposium - Moscone South, Esplanade Ballroom
Saturday
4:30 PM -
4:45 PM 1235 - A Phase II Trial of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor OSI-774, Following Platinum-Based Chemotherapy, in Patients (pts) with Advanced, EGFR-Expressing, Non-Small Cell Lung Cancer (NSCLC).
Authors: Roman Perez-Soler, Abraham Chachoua, Mark Huberman, Daniel Karp, James Rigas, Lisa Hammond, Eric Rowinsky, G Preston, Karen J Ferrante, Lee F Allen, Paul I Nadler, Philip Bonomi, New York University School of Medicine, New York, NY; Beth Israel Deaconess
Faculty: Roman Perez-Soler
Lung Cancer: Small Cell and Non-Small Cell
Oral Presentation - Moscone South, Exhibit Level, Hall C
Sunday
1:30 PM -
5:30 PM 518 - Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Cetuximab (IMC-C225) in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.
Authors: James L. Abbruzzese, Arthur Rosenberg, Qinghua Xiong, Albert LoBuglio, William Schmidt, Robert Wolff, Michael Needle, Harlan Waksal, MD Anderson Cancer Center, Houston, TX; Greenwich Hospital, Greenwich, CT; Universtiy of Alabama at Birmingham, Birmingham
Faculty: James L. Abbruzzese
Gastrointestinal Cancer
Poster Discussion Session - Hilton, Continental Ballroom, Parlor 7
Peter |
